In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.

The free consultation period for this content is over.

It is now only available year-round to ACCA Ivory (& above) Members, Fellows of the ESC and Young combined Members

Cardiogenic shock due to acute severe mitral regurgitation: the role of a temporary ventricular support device as a bridge to definitive treatment

Session Moderated Cases 1: Acute heart failure, shock and more

Speaker Francisca Caetano

Congress : Acute Cardiovascular Care 2019

  • Topic : heart failure
  • Sub-topic : Acute Heart Failure: Non-pharmacological Treatment
  • Session type : Moderated Posters
  • FP Number : 23

Authors : F Caetano (London,GB), S Singh (London,GB), P Meier (London,GB), A Duncan (London,GB), R Smith (London,GB), N Moat (London,GB), R Trimlett (London,GB), S Uddin (London,GB), S Price (London,GB)


F Caetano1 , S Singh1 , P Meier2 , A Duncan2 , R Smith2 , N Moat3 , R Trimlett3 , S Uddin1 , S Price1 , 1Royal Brompton Hospital, Adult Intensive Care Unit - London - United Kingdom , 2Royal Brompton Hospital, Cardiology - London - United Kingdom , 3Royal Brompton Hospital, Cardiac Surgery - London - United Kingdom ,


Introduction: patients with acute mitral regurgitation (MR) are frequently critically ill with significant haemodynamic instability requiring urgent medical and/or surgical treatment. Intra-aortic balloon counterpulsation (IABP) has historically been used to support the circulation prior to cardiac surgery, but in very severe MR the level of support may be insufficient. This case describes the use of percutaneous mechanical circulatory support (MCS) with Impella® to facilitate successful percutaneous mitral valve repair in a patient with cardiogenic shock (CS).

Case Study: a 59-year-old woman presented to the emergency department severely hypoxic with 1 day history of cough and breathlessness and radiological evidence of right-sided pulmonary consolidation suggesting community acquired pneumonia. She was initiated on antibiotics and non-invasive ventilation, however she deteriorated within 48 hours requiring invasive ventilation and multi organ support. Initial FoCUS demonstrated eccentric severe MR with one image suggesting a possible vegetation on the mitral valve.

 She was transferred for further management to a regional cardiothoracic centre. Her transesophageal echocardiogram revealed torrential MR due to flail of P3 with a ruptured chordae and P2 prolapse (Image 1), a low cardiac output despite an apparently hyperdynamic LV,  and no features of infective endocarditis. An Impella® 2.5 was inserted as a bridge to definitive treatment.

She was discussed by the MDTs (shock team, mitral team, critical care, specialist imaging) and after significant improvement (complete resolution of pulmonary oedema, minimal inotropes, normalisation of liver and kidney function), underwent successful percutaneous mitral valve repair day 10 post-admission. She was successfully extubated on day 1 and ultimately discharged home 19 days after initial presentation. 

Conclusions: In CS, current guidelines recommend inotropes, respiratory support and early implementation of MCS, alongside with interventions to reverse the underlying cause. Mortality remains high in severe MR with the use of IABP alone, likely related to the degree of unresolved pulmonary oedema and poor organ perfusion resulting in multi-organ failure. Where right ventricular dysfunction is not a concern, devices such as the Impella®, might offer more favourable haemodynamic support and reverse organ dysfunction.

 Another important consideration in severe MR are the numerous novel percutaneous interventions which are in development, highlighting the necessity of early expert imaging  and multi-specialist team consultations  to create an individualised management strategy and  thus optimise outcomes.

The free consultation period for this content is over.

It is now only available year-round to ACCA Ivory (& above) Members, Fellows of the ESC and Young combined Members

Based on your interests

Three reasons why you should become a member

Become a member now
  • 1Access your congress resources all year-round on the New ESC 365
  • 2Get a discount on your next congress registration
  • 3Continue your professional development with free access to educational tools
Become a member now

Our sponsors

ESC 365 is supported by Bayer, Boehringer Ingelheim, Bristol-Myers Squibb and Pfizer Alliance, Novartis Pharma AG and Vifor Pharma. The sponsors were not involved in the development of this platform and had no influence on its content.

logo esc

Our mission: To reduce the burden of cardiovascular disease

Who we are